Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

879
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
879
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

450
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
450
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

602
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
602
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

1.4K
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
1.4K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic testing for cancer predisposition syndromes in pediatric cancer patients: current practices and recommendations - a systematic review.

Radiology and oncology·2026
Same author

From trial-and-error to inverse design: how AI is redefining drug delivery systems.

Drug discovery today·2026
Same author

Cooperative molecular interaction networks govern PARP1 inhibitor selectivity and binding affinity.

PLoS computational biology·2026
Same author

Correction to: Rational design of lipid-based nanoparticles for targeted anticancer therapies.

Drug delivery and translational research·2026
Same author

Guanidine-Based Ligands in Bioinorganic Chemistry: Coordination Modes and Applications in Anticancer Metallodrugs.

Bioinorganic chemistry and applications·2026
Same author

Corrigendum to "Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation" [Biomed. Pharmacother. 178 (2024) 117165].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: Mar 31, 2026

Experimental Investigation of Secondary Flow Structures Downstream of a Model Type IV Stent Failure in a 180° Curved Artery Test Section
11:00

Experimental Investigation of Secondary Flow Structures Downstream of a Model Type IV Stent Failure in a 180° Curved Artery Test Section

Published on: July 19, 2016

12.0K

Failures in Phase III: Causes and Consequences.

Bostjan Seruga1, Alberto Ocana2, Eitan Amir3

  • 1Department of Medical Oncology, Institute of Oncology Ljubljana and University of Ljubljana, Ljubljana, Slovenia.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 17, 2015
PubMed
Summary
This summary is machine-generated.

Oncology drug development faces challenges, with many late-stage trials failing. Stricter early-phase evidence of efficacy is needed to improve cancer therapy success rates and protect patients.

More Related Videos

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models
10:49

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models

Published on: June 16, 2022

3.1K
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.7K

Related Experiment Videos

Last Updated: Mar 31, 2026

Experimental Investigation of Secondary Flow Structures Downstream of a Model Type IV Stent Failure in a 180° Curved Artery Test Section
11:00

Experimental Investigation of Secondary Flow Structures Downstream of a Model Type IV Stent Failure in a 180° Curved Artery Test Section

Published on: July 19, 2016

12.0K
Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models
10:49

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models

Published on: June 16, 2022

3.1K
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.7K

Area of Science:

  • Oncology
  • Clinical Trials
  • Drug Development

Background:

  • Phase III randomized controlled trials (RCTs) in oncology have a lower success rate for drug registration compared to other disciplines.
  • The pharmaceutical industry heavily sponsors most oncology RCTs, highlighting their central role in cancer drug development.
  • Preclinical models for evaluating anticancer agents are often unreliable, necessitating stronger biologic effect evidence before clinical trials.

Discussion:

  • Early-phase clinical trials should incorporate pharmacodynamic studies to confirm target inhibition and antitumor activity.
  • Many targeted anticancer agents entering Phase III trials lack sufficient early-phase evidence of efficacy.
  • Initiating Phase III trials without robust early-phase data can potentially harm patients.

Key Insights:

  • A significant number of targeted anticancer agents have failed in recent Phase III RCTs.
  • Many approved oncology drugs offer only improved progression-free survival, not overall survival or quality of life benefits.
  • Decisions to advance drugs from Phase II to III and to marketing approval require higher standards of evidence.

Outlook:

  • Implementing value-based pricing could discourage development of agents with marginal early-phase activity.
  • Oncologists must critically evaluate industry collaborations and advocate for patient interests.
  • Future oncology drug development should prioritize agents with demonstrated substantial clinical benefit based on rigorous early-phase data.